Skip to main navigation
Skip to search
Skip to main content
Houston Methodist Scholars Home
Home
Experts
Research units
Cores
Projects
Research output
Prizes
Search by expertise, name or affiliation
View Scopus Profile
Martyn A. Sharpe, PhD
John S. "Steve" Dunn, Jr. Distinguished Professorship in Brain Tumor Research
,
Department of Neurosurgery
Associate Research Professor of Neurosurgery
,
Academic Institute
Associate Research Member
,
Research Institute
Kenneth R. Peak Brain & Pituitary Treatment Center
Neurological Institute
Houston Methodist
Email
masharpe
houstonmethodist
org
h-index
3268
Citations
31
h-index
Calculated based on number of publications stored in Pure and citations from Scopus
1990 …
2023
Research activity per year
Overview
Fingerprint
Network
Projects
(1)
Research output
(83)
Similar Profiles
(6)
Research output
Research output per year
1990
1996
1997
1998
2000
2002
2003
2020
2021
2023
73
Article
3
Patent
2
Chapter
2
Conference contribution
3
More
2
Review article
1
Short survey
Research output per year
Research output per year
3 results
Publication Year, Title
(descending)
Publication Year, Title
(ascending)
Title
Type
Filter
Patent
Search results
2022
METHOD AND APPARATUS FOR ONCOMAGNETIC TREATMENT
Helekar, S. A.
,
Baskin, D. S.
,
Sharpe, M. A.
&
Pichumani, K.
,
Jun 23 2022
, IPC No. A61N 2/ 12 A I, Patent No. US2022193436, Priority date
Dec 31 2021
, Priority No. US202117567101
Research output
:
Patent
neoplasms
100%
magnetic fields
77%
cell death
60%
apoptosis
60%
neoplasm cells
59%
2021
METHOD AND APPARATUS FOR ONCOMAGNETIC TREATMENT
Helekar, S. A.
,
Baskin, D. S.
,
Sharpe, M. A.
&
Pichumani, K.
,
Sep 22 2021
, IPC No. A61N 2/ 12 A I, Patent No. EP3880299, Priority date
Nov 13 2019
, Priority No. WO2019US61131
Research output
:
Patent
2013
COMPOUND COMPRISING A MAO TARGETING/SEEKER MOIETY FOR TREATING HUMAN GLIOMAS
Baskin, David, S.
&
Sharpe, Martyn, A.
,
Oct 10 2013
, IPC No. A61K 31/ 4375 A I, Patent No. CA2887928, Priority date
Oct 31 2012
, Priority No. WO2012US62850
Research output
:
Patent
Monoamine
100%
Antineoplastic Agent
76%